All In Biotech

Drug Trial Radar · NCT06918743

To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of RSS0393 Ointment Local Administration in Adults With Chronic Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of RSS0393 ointment in patients with plaque psoriasis Phase II study

Conditions

  • Psoriatic Subjects

Interventions

  • RSS0393 ointmentDrug

    RSS0393 ointment 0.01%

  • RSS0393 ointmentDrug

    RSS0393 ointment 0.03%

  • RSS0393 ointment placeboDrug

    RSS0393 ointment placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with a clinician's overall assessment (PGA) response (defined as a PGA score of 0 (clear) or 1 (nearly clear) with ≥2 points improvement from baseline)Time frame: 8weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.